Walleye Trading
CRSP icon

Walleye Trading’s CRISPR Therapeutics CRSP Stock Holding History

Walleye Trading’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$718K Sell
15,086
-2,624
-15% -$138K ﹤0.01% 2353
2025
Q4 		$929K Buy
+17,710
New +$1.06M ﹤0.01% 2425
2025
Q2 		– Sell
-33,453
Closed -$1.29M – 4302
2025
Q1 		$1.14M Buy
+33,453
New +$1.42M ﹤0.01% 1978
2024
Q4 		– Sell
-8,870
Closed -$419K – 4308
2024
Q3 		$417K Buy
8,870
+7,173
+423% +$364K ﹤0.01% 2631
2024
Q2 		$91.7K Sell
1,697
-3,510
-67% -$203K ﹤0.01% 3402
2024
Q1 		$355K Buy
+5,207
New +$373K ﹤0.01% 3051
2022
Q1 		– Sell
-4,793
Closed -$301K – 5408
2021
Q4 		$363K Buy
4,793
+4,711
+5,745% +$412K ﹤0.01% 3266
2021
Q3 		$9K Sell
82
-10,390
-99% -$1.3M ﹤0.01% 5004
2021
Q2 		$1.7M Buy
+10,472
New +$1.27M 0.01% 1632
2020
Q1 		– Sell
-2,718
Closed -$140K – 4053
2019
Q4 		$166K Sell
2,718
-4,197
-61% -$229K ﹤0.01% 3279
2019
Q3 		$283K Buy
+6,915
New +$330K ﹤0.01% 2640
2019
Q1 		– Sell
-20,791
Closed -$719K – 4275
2018
Q4 		$594K Buy
+20,791
New +$723K ﹤0.01% 2305

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Walleye Trading's CRSP Position: Q1 2026 in Review

Walleye Trading reduced its CRISPR Therapeutics (CRSP) stake by 15% in Q1 2026, selling an estimated $138K and leaving 15,086 shares worth $718K. The position accounts for ﹤0.01% of the portfolio, ranked #2353.

Walleye Trading first reported a position in CRSP in Q4 2018 and has held it in 12 quarters since. The position peaked at $1.7M in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Walleye Trading held 15,086 shares of CRISPR Therapeutics worth $718K as of Q1 2026.
  • Walleye Trading sold 2,624 CRISPR Therapeutics shares in Q1 2026, an estimated $138K.
  • CRISPR Therapeutics made up ﹤0.01% of Walleye Trading's portfolio in Q1 2026, its #2353 holding.
  • Walleye Trading first reported a position in CRISPR Therapeutics in Q4 2018 and has held it in 12 quarters since.
  • Walleye Trading's CRISPR Therapeutics position peaked at $1.7M in Q2 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.